Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Retained Earnings (2016 - 2025)

Karyopharm Therapeutics' Retained Earnings history spans 14 years, with the latest figure at -$1.8 billion for Q4 2025.

  • For Q4 2025, Retained Earnings fell 505517.98% year-over-year to -$1.8 billion; the TTM value through Dec 2025 reached -$1.8 billion, down 505517.98%, while the annual FY2025 figure was -$1.8 billion, 505517.98% down from the prior year.
  • Retained Earnings reached -$1.8 billion in Q4 2025 per KPTI's latest filing, down from -$1.7 billion in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $372000.0 in Q3 2021 to a low of -$1.8 billion in Q4 2025.
  • Average Retained Earnings over 5 years is -$719.1 million, with a median of -$583.2 million recorded in 2021.
  • Peak YoY movement for Retained Earnings: surged 171.67% in 2021, then plummeted 505517.98% in 2025.
  • A 5-year view of Retained Earnings shows it stood at -$1.2 billion in 2021, then soared by 99.95% to -$638000.0 in 2022, then skyrocketed by 74.76% to -$161000.0 in 2023, then crashed by 121.12% to -$356000.0 in 2024, then tumbled by 505517.98% to -$1.8 billion in 2025.
  • Per Business Quant, the three most recent readings for KPTI's Retained Earnings are -$1.8 billion (Q4 2025), -$1.7 billion (Q3 2025), and -$251000.0 (Q2 2025).